Welcome to our dedicated page for Dss news (Ticker: DSS), a resource for investors and traders seeking the latest updates and insights on Dss stock.
DSS, Inc. reports developments across a diversified operating platform that includes Product Packaging, Biotechnology, Commercial Lending, and Securities & Investment Management. Company updates commonly address packaging operations, financial results, balance-sheet actions, common-stock offerings, and regulatory or audit disclosures.
News also covers subsidiary activity such as Sentinel Brokers Company, Inc., a FINRA-registered broker-dealer with fixed income trading, equity market-making, and approval to act as an underwriter and selling group member for corporate securities offerings.
DSS, Inc. (NYSE American: DSS) celebrates the successful IPO of Impact BioMedical Inc. (NYSE American: IBO), a company focused on healthcare and wellness solutions. The IPO was priced at $3.00 per share for 1,500,000 shares, with trading beginning on September 16, 2024 on the NYSE American Market. This milestone enhances shareholder value for DSS investors.
Key points:
- DSS distributed 4 shares of Impact BioMedical for every 1 DSS share held on July 10, 2023
- Underwriters received warrants to purchase up to 75,000 shares (or 86,250 if over-allotment is exercised)
- Warrants are exercisable at 125% of IPO price from 9 months after offering until the 3rd anniversary
Jason Grady, Interim CEO of DSS, expressed pride in Impact BioMedical's success and its alignment with DSS's commitment to shareholder returns.
AmericaFirst Funds, a subsidiary of DSS, Inc. (NYSE American: DSS), announced changes to its Board of Trustees. Three independent directors resigned on August 9, 2024, and three new directors were elected by shareholder proxy vote: Dr. Prabir Datta, Darryl Robinson, and Mark Gronet.
The new directors bring extensive experience in asset management, risk management, investment operations, and sales. Dr. Datta has a background in finance and operations, Robinson is a real estate industry veteran, and Gronet has expertise in institutional sales and human resources. These appointments aim to enhance the Trust's expertise and support its growth and success in the evolving investment landscape.
DSS, Inc. (NYSE American: DSS) has appointed Jason Grady as Interim CEO, effective August 23, 2024. Grady, previously COO, succeeds Frank D. Heuszel, who is transitioning to a leadership role at Impact Biomedical, a former DSS subsidiary. With over 25 years of executive experience, Grady has held key positions within DSS, including CEO of DSS Biohealth Holdings and President of Premier Packaging
Grady aims to lead DSS into its next growth phase, focusing on operational efficiency, revenue generation, and reducing cash burn. He acknowledges past challenges and is committed to enhancing shareholder value. This leadership change marks a pivotal moment for DSS as it navigates the evolving business landscape and strives to turn challenges into opportunities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.